001     299547
005     20250515140519.0
024 7 _ |a 10.1007/s10865-025-00559-w
|2 doi
024 7 _ |a pmid:40042752
|2 pmid
024 7 _ |a 0160-7715
|2 ISSN
024 7 _ |a 1573-3521
|2 ISSN
037 _ _ |a DKFZ-2025-00491
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Meissner, Valentin H
|0 0000-0001-7679-3658
|b 0
245 _ _ |a Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial.
260 _ _ |a Dordrecht [u.a.]
|c 2025
|b Springer Science + Business Media B.V.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1747310668_1549
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Jun;48(3):464-477
520 _ _ |a Cancer worry and risk perception are relevant psychological factors that influence preventive health behaviors. Therefore, a thorough understanding of the factors that impact their occurrence and manifestation is critical. The objective of this study was to assess prevalence and factors associated with worry about prostate cancer (PCa) and absolute/comparative risk perception in a community-based sample of 45-year-old men. Data were collected within the German PCa screening trial PROBASE. Variables were assessed by self-report questionnaires and a clinical interview. Worry about PCa and absolute/comparative risk perception were assessed each on a 5-point-Likert scale. Multivariable logistic regression was used to identify factors associated with the outcomes of interest. Data were available for 33,476 (72.0%) of 46,495 men at enrollment. 7.3% had sometimes/(very) often worry about PCa. 3.7% and 9.9% perceived their absolute risk and comparative risk as somewhat high/very high and somewhat higher/much higher, respectively. 18.8% reported a positive PCa family history. Important factors of worry about PCa, absolute risk perception, and comparative risk perception were lower urinary tract symptoms (LUTS) (OR 3.00, 95% CI 2.63-3.42; OR 2.09, CI 1.71-2.56; OR 2.41, CI 2.10-2.76) and a positive PCa family history (OR 2.35, CI 2.08-2.65; OR 15.13, CI 12.73-17.97; OR 9.69, CI 8.76-10.72). A positive history of urological (OR 3.85, CI 2.63-5.63) and non-urological cancers (OR 1.97, CI 1.52-2.54) were associated with a higher comparative risk perception. In conclusion, worry about PCa and risk perception are influenced by non-cancer-related symptoms as well as by a positive PCa family history. These findings need to be addressed in risk communication with patients.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Absolute risk perception
|2 Other
650 _ 7 |a Cancer worry
|2 Other
650 _ 7 |a Comparative risk perception
|2 Other
650 _ 7 |a Family history
|2 Other
650 _ 7 |a Lower urinary tract symptoms
|2 Other
650 _ 7 |a Prostate cancer
|2 Other
700 1 _ |a Dinkel, Andreas
|b 1
700 1 _ |a Kron, Martina
|b 2
700 1 _ |a Schiele, Stefan
|b 3
700 1 _ |a Jahnen, Matthias
|b 4
700 1 _ |a Lakes, Jale
|b 5
700 1 _ |a Radtke, Jan Philipp
|b 6
700 1 _ |a Kuczyk, Markus A
|b 7
700 1 _ |a Harke, Nina N
|b 8
700 1 _ |a Debus, Jürgen
|b 9
700 1 _ |a Fink, Christoph A
|b 10
700 1 _ |a Antoch, Gerald
|b 11
700 1 _ |a Schimmöller, Lars
|b 12
700 1 _ |a Kristiansen, Glen
|b 13
700 1 _ |a Krilaviciute, Agne
|0 P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315
|b 14
700 1 _ |a Seibold, Petra
|0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
|b 15
700 1 _ |a Behrens, Sabine
|0 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
|b 16
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 17
700 1 _ |a Arsov, Christian
|b 18
700 1 _ |a Hadaschik, Boris
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Becker, Nikolaus
|0 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
|b 20
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 21
700 1 _ |a Albers, Peter
|0 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
|b 22
700 1 _ |a Gschwend, Jürgen E
|b 23
700 1 _ |a Herkommer, Kathleen
|b 24
773 _ _ |a 10.1007/s10865-025-00559-w
|0 PERI:(DE-600)2016730-1
|n 3
|p 464-477
|t Journal of behavioral medicine
|v 48
|y 2025
|x 0160-7715
909 C O |p VDB
|o oai:inrepo02.dkfz.de:299547
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-13
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-13
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-13
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
|d 2024-12-13
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J BEHAV MED : 2022
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-13
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-13
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-13
920 1 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 1
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 2
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C130-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21